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Super-refractory status epilepticus (SE) is characterized by
unresponsiveness to initial anaesthetic therapy. This deﬁnition
encompasses a SE that continues or recurs 24 h or more after the
onset of anaesthetic therapy and includes those cases in which SE
recurs on the reduction or withdrawal of anaesthesia. Treatment is
difﬁcult due to the failure of ﬁrst- and second-line therapy. As no
controlled or randomized studies are available on this phenome-
non, further therapeutic management is based on clinical reports
and expert opinion.1
The ketogenic diet (KD) is a high-fat, low-carbohydrate and
adequate protein diet that has been an established, effective non-
pharmacological treatment in the management of refractory
epilepsy and severe childhood encephalopathies since the early
1920s. The KD alters the primary cerebral energy metabolism from
glucose to ketone bodies and probably has multiple mechanisms of
antiepileptic action.2
Emergency use of KD has been reported predominantly in
children with SE.3,4 In adults only ﬁve case reports on prolonged SE
have been published.5–8 The KD should probably be tried in all
severe cases of super-refractory SE.1 Patients usually receive a
commercial enteral KD preparation (4:1 or 3:1 ketogenic ratio:
grams of fat to protein and carbohydrates combined), which is
usually administered via a gastric or gastrostomy tube, provided
the patient tolerates tube feeds well.* Corresponding author at: Department of Neurology and Epilepsy Center Hessen,
Philipps-University Marburg, Baldingerstrasse, 35043 Marburg, Germany.
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1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.03.007We report a case in which a KD was started intravenously
leading to subsequent ketosis in an adult patient with super-
refractory status epilepticus and intestinal dysmotility.
2. Case report
This female patient initially presented at the age of 14 years
with myoclonus and generalized tonic–clonic seizures. Over the
previous 7 years no seizure remission had been achieved on
various combinations of anticonvulsant drugs or treatment with
vagus nerve stimulation. Furthermore, disturbance in gait (ataxia)
and cognitive decline were rapidly progressing. Subsequently a
mutation in the EPM2A gene and thus a diagnosis of Lafora disease
was established.
At the age of 21 years she presented with a generalized,
convulsive SE. At admission the anticonvulsive regimen was
valproate 780 mg/d, levetiracetam 4000 mg/d, topiramate 250 mg/
d and clonazepam 9 mg/d (Fig. 1a). The treatment of SE required
generalized anaesthesia with propofol (200 mg/h), which had to be
discontinued due to 8II atrioventricular block. Adequate sedation
could not be achieved with midazolam (100 mg/h) and ﬁnally
thiopental (500 mg/h) anaesthesia was established for 48 h. Over
the next 15 days, she continued to have frequent myoclonic and
generalized tonic–clonic seizures without recovery to baseline
mental status. Multiple routine EEGs showed periodic generalized
epileptiform discharges pointing to the diagnosis of ongoing SE
(Fig. 1b). The anticonvulsive regimen was switched to valproate
960 mg/d, levetiracetam 4000 mg/d, zonisamide 600 mg/d, pirac-
etam 7000 mg/d and clonazepam 9 mg/d. On hospital day 7,
treatment with steroids over 5 days (methylprednisolone
1000 mg/d) was started and magnesium was added on hospital
day 15 without resolution of SE. Magnesium had to be
discontinued after 8 h due to reoccurrence of 8II atrioventricular
block. On hospital day 16 the patient went into another
generalized, convulsive SE that could not be controlled with
midazolam up to 250 mg/h. Again thiopental (500 mg/h) anaes-
thesia was established for 48 h.
2.1. Intravenous emergency ketogenic diet induction
Upon infusion of thiopental, parenteral nutrition was stopped
and a fasting period of 6 h was started in preparation forvier Ltd. All rights reserved.
Fig. 1. (a) Timing of administration of different compounds and clinical course. (b)
EEG with periodic generalized epileptiform discharges and associated decrement
during status epilepticus. (c) EEG with bifrontal polyspikes and generalized slowing
after achieving ketosis.
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feeds and had prominent reﬂux intravenous administration of KD
was preferred. The patient received a KD with 1000 kcal during the
ﬁrst 24 h and 1500 kcal/d on the following days according to
Table 1. The KD was infused continuously over 16 h and was
stopped for 8 h at nighttime. Glucose-free solutions such as saline
were also given as required. The KD had a 4:1 ketogenic ratio and
was composed of commercially available fat emulsion with
medium-chain triglycerides (Lipofundin 20% with MCT, B. Braun
Melsungen, Germany), amino acid (Aminoplasmal 10%, B. Braun
Melsungen, Germany) and carbohydrate (Glucose 5%, B. Braun
Melsungen, Germany) solutions for intravenous application. There
was no hypoglycaemia or acidosis upon starting the KD. Urine
ketones were detected (urine stix: +) after 3.5 days and persisted athigh concentrations from day 4 onwards (urine stix: ++++). Ketone
bodies were conﬁrmed in the plasma with a b-hydroxybutyrate
level of 3627 mmol/l and acetoacetate of 1705 mmol/l. Parenteral
administration of KD was continued until hospital day 27 and then
switched to an enteral preparation administered via gastrostomy
tube. The commercially available KetoCal 4:1 LQ Multi Fibre
237 ml (Nutricia GmbH, Heilbronn, Germany) was given 5 times
per day resulting in a total daily intake of 1780 kcal. Subsequently
the patient and EEG (Fig. 1c) improved. Her mental status gradually
recovered to baseline. She continued to have daily myoclonus, and
generalized tonic–clonic seizures occurred every 3–4 days. On
hospital day 47 she was discharged and no further episodes of
status epilepticus were reported during the 4-month follow-up.
3. Discussion
We report a case treated with a total parenteral KD and
subsequent ketosis in super-refractory SE. Initiation of KD resolved
the SE, which was refractory to multiple anticonvulsants,
anaesthetics, steroids and magnesium. To the best of our
knowledge, this is the ﬁrst reported case of intravenous KD for
the treatment of SE. Administration of KD was safe and feasible
with commercially available fat emulsion containing medium-
chain triglycerides as well as amino acid and carbohydrate
solutions. Ketosis was achieved within 3.5 days and was
maintained for a further 6 days via the intravenous route of
administration. We did not observe any hypoglycaemia, acidosis or
any other complications. However, the relationship between the
KD and resolution of SE is not absolutely certain given the
considerable amount of confounding factors.
A retrospective study9 reported on the successful maintenance
of ketosis using ketogenic parenteral nutrition in 10 children with
intractable epilepsy who required bowel rest due to vomiting,
severe diarrhoea, intolerability of a nasogastric tube or intestinal
bleeding. The mean duration of the ketogenic parenteral nutrition
was 4.1 days and it could be successfully changed back to enteral
KD later on. The authors used conventional intravenous fat
emulsion (20% Lipision, long-chain triglyceride) plus dextrose
and amino acid (6% TrophAmine) hyperalimentation available in
South Korea.9
The preparation of parenteral KD should be feasible everywhere
with commercially available, standard intravenous solutions.
Larger studies are warranted to better understand the efﬁcacy
and tolerability of parental KD, and its potential use in SE.
Parenteral KD proved to be a relatively safe short-term method in
our adult case and in the reported study on children.9
In conclusion, our case suggests that parenteral initiation of
ketosis can be successfully implemented in critically ill patients
and might simplify access to this treatment alternative in super-
refractory status epilepticus.
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Table 1
Total parenteral ketogenic diet (ratio 4:1).
Solution Total volume Infusion ratea Weight Calories
KD 1000 kcal/d
Fat Lipofundin 20% 500 ml 32 ml/h 100 g fat 950 kcal
Amino acids Aminoplasmal 10% 150 ml 10 ml/h 15 g amino acids 60 kcal
Carbohydrates Glucose 5% 200 ml 12 ml/h 10 g carbohydrates 34 kcal
Total 850 ml 54 ml/h 125 g 1044 kcal
KD 1500 kcal/d
Fat Lipofundin 20% 750 ml 47 ml/h 150 g fat 1425 kcal
Amino acids Aminoplasmal 10% 225 ml 14 ml/h 22.5 g amino acids 90 kcal
Carbohydrates Glucose 5% 300 ml 15 ml/h 15 g carbohydrates 51 kcal
Total 1275 ml 79 ml/h 187.5 g 1566 kcal
a Infusion rate for 16 h and 8 h of fasting per day.
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